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Avian Influenza Vaccination 

Sherrill Davison, VM.D" Phillip Scott, 
Ph. D., and Robert 1. Eckroade, D. VM. 
Avian Influenza (AI) is a v iral res­piratory diseuse of many species of domestic and wild birds. His­
torically, in commercia l poultry flocks, 
turkeys are most commonly affected due 
to the practice of range rearing and co­
mingling with wild birds . While only six 
outbreaks of Al have occurred in com­
mercial chickens in the U nited States 
prior to the current 1997 outbreak, when 
they occur they can be devastating. The 
1983-1984 AI outbreak in Pennsylvania 
resulted in the depopulation of 17 mil­
lion birds with a cost to the federal gov­
ernment of $60 million . 
The recent AI outbreak in Pennsylvania 
began in December 1996 when a live bird 
market dealer 's /lock in Lebanon County 
was found to b positi ve for nonpathogenic 
AI (H7N2). Subsequent to that , a flock of 
commercial layers in the same vicinity was 
diagnosed with nonpathogenic AI (H7N2). 
Then in April 1997, a flock of commercial 
layers was diagnosed with AI in Lancaster 
County. A quarantine was placed on poul­
try facilities in a five mile radius of the in­
dex tlock in Lancaster County. To date, a 
total of 19 commercial layer flocks, two 
commercial layer pullet tlocks, and a com­
mercial meat turkey flock have been diag­
nosed with non-pathogenic AI (H7N2) 
viral infection. 
Control of avian influenza includes 
depopulation , quarantine and vaccina­
tion. Research and field experience 
(Mexico and the United States) has 
shown that vaccination for avian influ­
enza can decrease the clinical signs of 
avian influenza, decrease the viral shed 
from known infected birds and therefore 
decrease the potential transmission of the 
disease to surrounding flocks. 
Avian influenza vaccination has not 
Identification ofgene defect leads to cystinuria test 

The gene de fect for cystinuria in 
Newfoundlands has been identified by 
Dr. Pau la Henthorn, u. ociate professor 
of medical genetics, and colleagues in 
the Section of Medical Genetics at 
Penn 's School of Veterinary Medicine. 
The team, which includes Dr' . Urs 
G iger and Jung Long Lin . has deve l­
oped a test t identify carriers, affected. 
and normal dogs fo r the disease in ew­
foundlands . Cyst inuria, which also af­
fects many other breeds. is an 
autosomal recessive trait. 
The molecular te t is the sixth such 
test the Penn group has developed. New­
foundland breeders can now screen their 
br eding stock for thi . disease to reduce 
the numher of affe tcd animals. If all 
breeding animals are screened, the dis­
ease can be elimi nated from the New­
foundland population in the relatively 
short period or nne to two generations. 
Cystinuria is caus d by excessive 
urinary excretion J[' c st ine and other 
amino acids due to a defective transport 
system for these ~ubs tances in the kid­
ney. It leads to crystal and eventual 
stone (bladder and kidney stones) for­
mation in the urinary tract and is par­
ticularly problematic in male dogs. 
Dr. Henthorn and her colleagues are 
now working to identify the gene de­
fects causing cystinuria in other affected 
breeds so that additional tests can be de­
veloped. Unfortunately, in genetic dis­
ea 'e ', the gene defect ~ r a di sease and 
its location vary from breed to breed, 
requi ring much painstaking research to 
develop tests for each breed. 
Dr. Henthorn's work On cystinuria i: 
supported by grants from the National 
Institutes of Health and the AKC Ca­
nine Health Foundation. The test for 
cystinuria in Newfoundlands is one of 
the many tests for canine and feline ge­
netic diseases available through the 
Josephine Deubler Genetic Disease 
Testing Laboratory in the Section of 
Medical Genetics, School of Veterinary 
Medicine, University of Pennsylvania. 
For additional information, contact Dr. 
rs Giger at 215-898-3375(phone), 
21 5-573-2162 (fax) or via e-mail 
at<penngen@vet.upenn.edu>. 
been approved for use in the United States 
in chickens unless the virus is highly 
pathogenic. The use of vaccine in Penn­
sylvania during the 1997 avian influenza 
outbreak was denied because the virus 
was classified as nonpathogenic. Cur­
rently, the only available vaccine for use 
in commercial pOUltry is a killed product. 
Additional vaccines under development 
are the fowl pox viral vectored vaccine 
and sub-unit protein vaccines. 
Major advances in our understanding of 
vaccines have occurred due to basic mo­
lecular studies, and are currently being ap­
plied to the improvement of vaccines 
against many human diseases. One of the 
most exciting advances in the development 
of new vaccines has been the discovery 
that injection of DNA-encoding viral anti­
gens that are known to be protective - can 
induce protection that is equivalent to, or 
superior to, that obtained following immu­
nization with killed whole organisms, puri­
fied proteins, or subunit vaccines. 
There are several notable advantages to 
using DNA vaccines over conventional pro­
tein antigens, some of which include: 1) the 
ease of manufacturing the vaccine; 2) the sta­
bility of the vaccine; 3) providing long-term 
antigen expression that continuously stimu­
lates the immune response; 4) the lack of a 
requirement for a traditional adjuvant; 5) the 
ability of DNA vaccines to stimulate both 
strong antibody responses, T cell responses 
and the generation of cytotoxic T cells; and 6) 
the ability to co-deliver the vaccine with pJas­
rnid-DNA-encoding cytokines to enhance the 
immune response. Of particular interest has 
been the inclusion of cytokines, one of the 
most important of which is interleukin-12 
(lL-12) which, when administered in a vac­
cine, dramatically improves the efficacy. U n­
fortunately, these advances have been slow to 
be applied to food animals, where they could 
make a major impact in the agricultural in­
dustry. Our research wLll focus on the devel­
opment of a molecularly defmed avian 
influenza vaccine that incorporates IL-12, 
and compare the efficacy of such a vaccine 
with a commercially available killed vaccine. 
Development of a ON A vaccine will provide 
the basic information and tools necessary to 
offer the poultry industry of Pennsylvania the 
most effective vaccine available against avian 
influenza. 
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